SCHEMBL3604262

SCHEMBL3604262

CCN1Cc2c(N)cccc2NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.44
MMP13 P45452 1/20 0.44
BRD4 O60885 2/20 0.36
CREBBP Q92793 1/20 0.36
PARP1 P09874 2/20 0.34
TNF P01375 1/20 0.34
IL1B P01584 1/20 0.34
IKZF1 Q13422 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
IKZF3 Q9UKT9 1/20 0.34
CDK5 Q00535 2/20 0.33
CDK5R1 Q15078 2/20 0.33
DRD2 P14416 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594623 0.82 ACE (0.45) ACEMMP13BRD4CREBBPPARP1
SCHEMBL3600610 0.81 PARP1 (0.41) ACEMMP13BRD4CREBBPPARP1
SCHEMBL13545356 0.80 ACE (0.46) ACEMMP13BRD4CREBBPDRD2
SCHEMBL3598102 0.79 BRD4 (0.54) ACEMMP13BRD4CREBBPPARP1
SCHEMBL3594499 0.77 ACE (0.40) ACEMMP13LMNACYP2C9MAPK1
SCHEMBL1949749 0.74 BRD4 (0.44) BRD4PARP1TNFIL1BIKZF1
SCHEMBL30970866 0.73 BRD4 (0.61) BRD4CREBBPPARP1CDK5CDK5R1
SCHEMBL10668472 0.73 BRD4 (0.61) BRD4CREBBPPARP1CDK5CDK5R1
SCHEMBL16268392 0.72 HTR1A (0.37) PARP1KDM4ELMNAHTR1ATSHR
SCHEMBL16268697 0.69 PARP1 (0.36) PARP1KDM4ELMNAHTR1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed
CN-101589038-A Heterocyclidene-N-(aryl)acetamide derivative MOCHIDA PHARM CO LTD (JP) 2009-11-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 ACE 2551/4885MMP13 1538/4885BRD4 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.